CA2440196A1 - Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease - Google Patents

Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease Download PDF

Info

Publication number
CA2440196A1
CA2440196A1 CA002440196A CA2440196A CA2440196A1 CA 2440196 A1 CA2440196 A1 CA 2440196A1 CA 002440196 A CA002440196 A CA 002440196A CA 2440196 A CA2440196 A CA 2440196A CA 2440196 A1 CA2440196 A1 CA 2440196A1
Authority
CA
Canada
Prior art keywords
compound
adenosine
neurotrophic activity
receptor antagonist
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002440196A
Other languages
English (en)
French (fr)
Inventor
Dan Peters
Lars Christian Ronn
Karin Sandager Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2440196A1 publication Critical patent/CA2440196A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
CA002440196A 2001-04-09 2002-04-04 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease Abandoned CA2440196A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200100583 2001-04-09
DKPA200100583 2001-04-09
PCT/DK2002/000228 WO2002080957A1 (en) 2001-04-09 2002-04-04 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
CA2440196A1 true CA2440196A1 (en) 2002-10-17

Family

ID=8160425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002440196A Abandoned CA2440196A1 (en) 2001-04-09 2002-04-04 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease

Country Status (8)

Country Link
US (1) US7160899B2 (de)
EP (1) EP1379269B1 (de)
JP (1) JP2004529916A (de)
AT (1) ATE424194T1 (de)
CA (1) CA2440196A1 (de)
DE (1) DE60231386D1 (de)
MX (1) MXPA03009185A (de)
WO (1) WO2002080957A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144931A1 (en) * 2007-05-30 2008-12-04 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4910500A (en) * 1999-05-19 2000-12-12 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
WO2002064139A1 (en) * 2001-02-15 2002-08-22 Neurosearch A/S Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
EP2942082B1 (de) * 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd A2a rezeptor antagonisten zur verwendung in der behandlung von bewegungsstörungen
CN100415217C (zh) 2002-12-19 2008-09-03 先灵公司 腺苷A2a受体拮抗剂的应用
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
PL2026803T3 (pl) 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
RU2454409C2 (ru) * 2007-03-14 2012-06-27 Нопп Ньюросайенсиз, Инк. Синтез хирально очищенных замещенных бензотиазолдиаминов
KR20110071064A (ko) 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
SI3019167T1 (sl) 2013-07-12 2021-04-30 Knopp Biosciences Llc Zdravljenje povišanih ravni eozinofilcev in / ali bazofilcev
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
WO2018170359A1 (en) * 2017-03-17 2018-09-20 University Of Virginia Patent Foundation Compositions and methods for treating peripheral nerve disease, disorders, and injuries
CN114901665A (zh) * 2019-12-26 2022-08-12 浙江春禾医药科技有限公司 三唑并三嗪衍生物在治疗疾病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325254A1 (de) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
US5574060A (en) 1993-08-12 1996-11-12 The United States Of America As Represented By The Department Of Health And Human Services Selective inhibitors of biogenic amine transporters
FR2734264B1 (fr) 1995-05-19 1997-08-01 Lafon Labor Utilisation de derives d'alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamide pour la fabrication d'un medicament inhibant la recapture de la dopamine et nouveaux composes pour cette utilisation
IL123583A (en) 1995-10-13 2003-07-31 Neurosearch As 3-substituted -8-azabicyclo [3,2,1] oct-2-ene derivatives, their preparation and pharmaceutical compositions containing them
RU2162469C2 (ru) 1995-11-02 2001-01-27 Ньюросерч А/С Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов
WO1997040035A1 (en) * 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
US6011070A (en) 1996-08-16 2000-01-04 Allelix-Pharm-Eco L.P. Slow-onset, long-lasting dopamine reuptake blockers
US5821386A (en) 1997-08-15 1998-10-13 Allelix-Pharm-Eco L.P. Compounds for treating cocaine abuse
US6001330A (en) 1997-09-12 1999-12-14 Elmaleh; David R. Diagnostic and therapeutic alkylenediamine compounds and process
AU2639299A (en) * 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
EP1079816A2 (de) * 1998-04-23 2001-03-07 Takeda Chemical Industries, Ltd. Pharmazeutische zusammensetzung mit neurotrophischer wirkung
BR0108611A (pt) 2000-02-25 2003-05-06 Hoffmann La Roche Moduladores de receptor de adenosina
AU2001259252A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Neuroprotective compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144931A1 (en) * 2007-05-30 2008-12-04 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels

Also Published As

Publication number Publication date
US7160899B2 (en) 2007-01-09
ATE424194T1 (de) 2009-03-15
JP2004529916A (ja) 2004-09-30
US20040097540A1 (en) 2004-05-20
EP1379269B1 (de) 2009-03-04
MXPA03009185A (es) 2004-02-17
EP1379269A1 (de) 2004-01-14
WO2002080957A1 (en) 2002-10-17
DE60231386D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
US7160899B2 (en) Adenosine A2A receptor antangonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease
Korecka et al. Neurite collapse and altered ER Ca2+ control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation
EP2281828A2 (de) Modifiziertes Erythropoietin enthaltende Zusammensetzungen
WO2008147551A1 (en) Methods and compositions for stimulating cells
SK161097A3 (en) Use of the immunophilin ligand for the preparation of agent to stimulate neuronal growth and regeneration at neuropathological conditions
ITRM960790A1 (it) Uso di sostanze che attivano il recettore del cntf ( fattore neurotro fico ciliare) per la preparazione di farmaci per la terapia della
US20040082555A1 (en) Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders
US20040063742A1 (en) Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
WO2009135091A1 (en) Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
JP6364484B2 (ja) 神経保護剤としてのＥｐｈＡ４阻害剤
AU2016366635A1 (en) VAP-1 inhibitors for treating pain
KR20140019361A (ko) 유효량의 （3ａＲ）－1，3ａ，8－트리메틸－1，2，3，3ａ，8，8ａ－헥사히드로피롤로〔2，3－ｂ〕인돌－5－일 페닐카바메이트 및 이의 제조방법
EP2609914A1 (de) Neue Verfahren zur Behandlung oder Vermeidung von Neurodegeneration
Wallin et al. Hypothalamic monoamines and neuropeptides in dementia
WO2001085981A2 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
WO2022025204A1 (ja) ＥｐｏＲアンタゴニストによる疾患の処置
US20170173108A1 (en) Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation
JP5555922B2 (ja) 脱毛を治療する、又は、脱毛の発症を遅らせるための組成物
US20100035820A1 (en) Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation
US20040023843A1 (en) Preventives/remedies for emotional disorders
Litwack Erythropoietin
PATIL Contribution of Indian scientists to pharmacological research in the USA and Canada
Di Chiara Differential effects of intravenous R, S-(±)-3, 4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its S (+)-and R ())-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core
JP2002249443A (ja) 情緒障害予防・治療薬
JP2002517447A (ja) 双極性障害の治療のためのｎｋ−１受容体アンタゴニストの使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued